CIBRA Capital Ltd lifted its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 359.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 216,775 shares of the health services provider's stock after buying an additional 169,616 shares during the period. Amedisys comprises about 6.9% of CIBRA Capital Ltd's holdings, making the stock its 7th largest position. CIBRA Capital Ltd owned approximately 0.66% of Amedisys worth $20,080,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its position in Amedisys by 56.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock worth $31,000 after purchasing an additional 120 shares during the period. Fifth Third Bancorp lifted its stake in shares of Amedisys by 68.1% during the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after buying an additional 141 shares in the last quarter. UMB Bank n.a. boosted its holdings in Amedisys by 100.0% in the 1st quarter. UMB Bank n.a. now owns 386 shares of the health services provider's stock worth $36,000 after buying an additional 193 shares during the period. Johnson Financial Group Inc. bought a new position in shares of Amedisys in the fourth quarter worth $55,000. Finally, Vestcor Inc bought a new position in Amedisys in the 4th quarter worth about $73,000. 94.36% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Wall Street Zen cut shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th. Royal Bank Of Canada reissued an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th. Finally, Stephens restated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $100.75.
Read Our Latest Report on AMED
Amedisys Price Performance
Shares of Amedisys stock traded down $0.42 on Wednesday, hitting $95.96. 720,830 shares of the company traded hands, compared to its average volume of 422,686. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27. The company has a market cap of $3.15 billion, a P/E ratio of 35.41, a P/E/G ratio of 1.34 and a beta of 0.94. The firm's 50-day simple moving average is $95.49 and its 200 day simple moving average is $92.82.
Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a net margin of 3.79% and a return on equity of 12.52%. The firm's revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.03 EPS. Analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.
Amedisys Profile
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
